These results strongly suggest that the dual administration of a HER2 small-molecule inhibitor and a monoclonal antibody directed against the HER2/neu receptor is beneficial for the treatment of HER2-amplified cervical cancer in clinical settings. Here, ERBB2 is linked to cervical carcinoma.